| Literature DB >> 32352966 |
Michael L McHenry1, Jacquelaine Bartlett1, Robert P Igo1, Eddie M Wampande2, Penelope Benchek1, Harriet Mayanja-Kizza3, Kyle Fluegge1, Noemi B Hall1, Sebastien Gagneux4,5, Sarah A Tishkoff6, Christian Wejse7,8, Giorgio Sirugo9, W Henry Boom10, Moses Joloba2, Scott M Williams1,11, Catherine M Stein1,10.
Abstract
Genetic studies of both the human host and Mycobacterium tuberculosis (MTB) demonstrate independent association with tuberculosis (TB) risk. However, neither explains a large portion of disease risk or severity. Based on studies in other infectious diseases and animal models of TB, we hypothesized that the genomes of the two interact to modulate risk of developing active TB or increasing the severity of disease, when present. We examined this hypothesis in our TB household contact study in Kampala, Uganda, in which there were 3 MTB lineages of which L4-Ugandan (L4.6) is the most recent. TB severity, measured using the Bandim TBscore, was modeled as a function of host SNP genotype, MTB lineage, and their interaction, within two independent cohorts of TB cases, N = 113 and 121. No association was found between lineage and severity, but association between multiple polymorphisms in IL12B and TBscore was replicated in two independent cohorts (most significant rs3212227, combined p = 0.0006), supporting previous associations of IL12B with TB susceptibility. We also observed significant interaction between a single nucleotide polymorphism (SNP) in SLC11A1 and the L4-Ugandan lineage in both cohorts (rs17235409, meta p = 0.0002). Interestingly, the presence of the L4-Uganda lineage in the presence of the ancestral human allele associated with more severe disease. These findings demonstrate that IL12B is associated with severity of TB in addition to susceptibility, and that the association between TB severity and human genetics can be due to an interaction between genes in the two species, consistent with host-pathogen coevolution in TB.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32352966 PMCID: PMC7217476 DOI: 10.1371/journal.pgen.1008728
Source DB: PubMed Journal: PLoS Genet ISSN: 1553-7390 Impact factor: 5.917
Cohort demographics and clinical measures.
| Variable | Total | Cohort 1 | Cohort 2 | p |
|---|---|---|---|---|
| Sample Size | 234 | 113 | 121 | - |
| Female | 102 (43.6%) | 51(45.2%) | 51(42.2%) | 0.65 |
| HIV+ | 77(32.9%) | 46 (40.7%) | 31(25.6%) | 0.014 |
| Age, years | 29.44 ± 8.9 | 29.74 ± 9.1 | 29.17 ± 8.9 | 0.62 |
| Age range, years | 15–70 | 16–67 | 15–70 | - |
| TBscore | 5.69 ± 2.21 | 5.86 ± 2.20 | 5.53 ± 2.21 | 0.25 |
Values are shown as N (%) or as mean ± SD.
*Comparisons between Cohort 1 and Cohort 2 were made using Pearson’s χ2 test and for continuous variables using Student’s t-test.
Fig 1TBscore across lineages.
Lines within each lineage show the median values. Mean TBscore (+/- S.D.) is 5.6 (+/- 2.2) for L4/Non-Ugandan; 5.4 (+/-2.4) for L3:Central Asia and 5.8 (+/-2.2) for L4.6/Uganda. These do not differ p = 0.71 (ANOVA).
Association between IL12B markers and TBscore, adjusted for HIV status.
| Cohort 1 | Cohort 2 | Combined | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Alleles | Notation | β (95% CI) | p | β (95% CI) | P | β (95% CI) | p | FDR threshold |
| rs3212227 | 3' UTR | 0.94 (0.08, 1.79) | 0.03 | 1.05 (0.25, 1.85) | 0.01 | 1.00 (0.44, 1.58) | 0.0006 | 0.0005 | |
| rs3212219 | Intron | 0.89 (0.04, 1.74) | 0.04 | 1.05 (0.25, 1.86) | 0.01 | 0.98 (0.43, 1.56) | 0.0007 | 0.0009 | |
| rs3212220 | Intron | 0.91 (0.01, 1.81) | 0.05 | 1.05 (0.25, 1.87) | 0.01 | 1.01 (0.40, 1.56) | 0.0011 | 0.0023 | |
| rs3213094 | Intron | 0.84 (–0.02, 1.71) | 0.06 | 1.05 (0.25, 1.85) | 0.01 | 0.98 (0.41, 1.55) | 0.0009 | 0.0019 | |
| rs6894567 | Intron | 1.00 (0.17–1.83) | 0.02 | 0.90 (0.11–1.70) | 0.03 | 0.97 (0.41–1.53) | 0.0008 | 0.0014 | |
All analyses coded using homozygous ancestral as 1 and one or more copies of the derived allele coded as 0.
The ancestral allele is bold in the table.
1 FDR corrected p value for q = 0.1 and LD corrected for r2 < 0.3 (213 SNPs)
Full regression model results for SLC11A1 marker rs17235409.
| Cohort 1 | Cohort 2 | Combined | ||||
|---|---|---|---|---|---|---|
| β (95% CI) | p | β (95% CI) | p | β (95% CI) | p | |
| rs17235409 (β3) | -2.53 (-4.29, -0.77) | 0.0057 | -1.85 (-3.29, -0.40) | 0.014 | -2.11 (-1.00, -3.23) | 0.00026 |
| L4.6/Ugandan(β2) | -1.43 (-3.36, 0.50) | 0.15 | -2.18 (-3.73, -0.63) | 0.0067 | -1.83 (-0.62, -3.03) | 0.00331 |
| HIV+ Status(β1) | 0.30 (–0.51, 1.11) | 0.47 | -0.47 (-1.39, 0.44) | 0.31 | 0.033 (-0.56, 0.63) | 0.911 |
| rs17235409*L4.6/Ugandan (combination of GG and L4.6/Ugandan) (β4) | 2.36 (0.21, 4.50) | 0.033 | 2.71(0.91, 4.51) | 0.0039 | 2.63 (1.25, 4.00) | 0.000225 |
rs17235409 is an exonic SNP at position 219259732 on chromosome 2. The ancestral allele is G and the derived is A.
Regression Model:
Y = β0 +β1X1 + β2X2 + β3X3 + β4 (X2X3) + ε
X1 = rs17235409, X2 = HIV+ Status, X3 = Ugandan Lineage.
†Model of inheritance (GG vs GA/AA as referent).
Fig 2Effects of rs17235409 (SLC11A1) genotype and lineage on TBscore.
The association of TB severity with lineage differs but only when stratified by genotype. TBscore is smaller in the Uganda lineage for individuals carrying a derived allele (GA or AA)(left panel) at SLC11A1 but larger for the ancestral genotype (GG) carriers (right panel). These results show the underlying bases of the significant interaction between rs17235409 and MTB lineage (p = 0.00022) with genotype and lineage effect directions differing when examining stratified data.